Sat.1: Boris Becker speaks about his time in prison. SAT.1 will air the world-exclusive interview with the tennis legend in the prime time

(Unterföhring, Germany): Boris Becker speaks about his time in prison. Shortly after returning to his home country, the German tennis legend will answer the questions that interest everyone exclusively on SAT.1. What was his life like in an English prison? Why did he end up in prison? What did he miss the most? What was he surprised not to miss? What did Boris Becker learn during his time in prison?
For this interview with Boris Becker, SAT.1 is changing its prime-time schedule on Tuesday, December 20th. The station will conduct the world’s only interview with the tennis legend for a special program titled “SAT.1 Spezial. Boris Becker”. Steven Gätjen will ask the questions. Boris Becker will answer.
SAT.1 Editor-in-Chief Juliane Eßling says: “Boris Becker is possibly German sport’s greatest hero. We are all aware of the incredible heights and the major setbacks in his life. We feel like we know him. SAT.1 will not talk about Boris Becker but with him. I am delighted that Boris Becker is trusting us to conduct the world’s first and only interview with him after what might have been the most difficult period of his life. For this very personal talk, we are happy to change our prime-time schedule on Tuesday.”
SAT.1 will conduct the interview in German and English. International broadcasters wishing to carry the interview are welcome to contact Red Arrow Studios International’s worldwide sales department at sales@redarrowstudios.com.
“SAT.1 Spezial. Boris Becker” – on Tuesday, December 20th, 2022, 20:15 pm CET on SAT.1 and Joyn.
Press Contact:
Christoph Körfer / Barbara Stefaner
Communications & PR
phone: +49 (0) 89 95 07 -1178 / -1128
email: christoph.koerfer@seven.one / barbara.stefaner@seven.one
www.presse.sat1.de
Photo Production & Editing
Stephanie Bruchner
Phone: +49 89 95 07 - 1166
E-mail: stephanie.bruchner@seven.one
SAT.1
Bilder

Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 14:06:26 CET | Press release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:59:31 CET | Press release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing.
Forum for a self-reliant and self-determined Europe - the "Sovereign Europe Forum"23.12.2025 08:40:47 CET | Press release
Entrepreneurs, top managers and leaders from United Europe e.V. and European Forum Alpbach (EFA) are founding the Sovereign Europe Forum i.G.
Digital Subsidiary of Austrian State Printing Company Wins Infrastructure Tender for German EU Digital Identity Wallet22.12.2025 15:12:30 CET | Press release
youniqx Identity, a digital subsidiary of the Austrian State Printing Company (OSD), has won a Europe-wide tender, together with partner companies, for the infrastructure of the German EU Digital Identity Wallet (EUDI-Wallet). EU member states are required by EU regulations to provide a national version of an EU-wide valid EUDI-Wallet by the end of 2026. Citizens will be able to use the EUDI-Wallet to prove their personal identity throughout the EU
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom

